You are here:Home-Inhibitors & Agonists-Membrane Transporter/Ion Channel-Exportin-1 (CRM1,XPO1)

Request The Product List ofExportin-1 (CRM1,XPO1) Exportin-1 (CRM1,XPO1)

Cat. No. Product Name CAS No. Information
PC-35581

Selinexor

1393477-72-9 Selinexor (KPT-330, KPT330) is a potent, orally available, selective inhibitor of nuclear export (SINE) targeting CRM1 (XPO1); demonstrates in vivo anti-leukaemic efficacy against T-ALL and acute myeloid leukaemia (AML) cells; triggers nuclear accumulation of multiple CRM1 cargo tumor suppressor proteins followed by growth arrest and apoptosis in MM cells, block c-Myc, Mcl-1, and NF-κB activity. Selinexor (KPT-330, KPT330) induces proteasome-dependent CRM1 protein degradation, upregulates CRM1, p53-targeted, apoptosis-related, anti-inflammatory and stress-related gene transcripts in MM cells.

Blood Cancer

Phase 3 Clinical

PC-61270

KPT-251

1388841-50-6 A small-molecule, selective inhibitor of nuclear export (CRM1 inhibitor;SINE) that exhibits potent antileukemic activity; induces apoptosis at nanomolar concentrations in a panel of human AML cell lines with negligible toxicity to normal hematopoietic cells.
PC-70229

Leptomycin B

87081-35-4 A potent and specific nuclear export inhibitor that binds to and inhibits CRM1 (XPO1); blocks the cell cycle and shows potent anti-tumor activity, blocks the nuclear export of many proteins including HIV-1 Rev, MAPK/ERK, and NF-κB/IκB, and inhibits the inactivation of p53.
PC-42151

KPT-8602 Z-isomer

1642300-78-4 The Z-isomer of Eltanexor (KPT-8602), which is a second-generation SINE with markedly reduced brain penetration compared to selinexor.
PC-42150

Eltanexor

1642300-52-4 A second-generation SINE, orally bioavailable Exportin 1 (XPO1,CRM1) inhibitor with markedly reduced brain penetration compared to selinexor (30-fold less); inhibits viability of human AML cell lines in vitro with IC50 of 20−211 nM, more active than the first-generation XPO1 inhibitor, selinexor; exhibits greater anti-leukemic efficacy against both leukemic blasts and LICs in AML patient-derived xenograft models, with no effect on normal hematopoietic stem and progenitor cell (HSPC) frequency.

Blood Cancer

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com